BioSpace News Archive

Vizient, Inc. announced the release of its 2018 Corporate Responsibility Report, prepared in accordance with the Global Report Initiative, the most widely adopted global standard for sustainability reporting.

Pharmacyte now has a cell line into which the gene for a putative cannabinoid prodrug-activating enzyme has been ‘transfected’ or inserted into the cell’s DNA.

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announced the publication of preclinical data of the company’s lantibiotic compound OG253,

First prize in each state is $3,000 and 30 Stop the Bleed kits, including the SAM XT Extremity Tourniquet famous for its Click, Twist & Secure ease of use.

Ayala Pharmaceuticals, a clinical-stage company developing medicines for cancers that are genetically defined, announced today that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) for AL101,

Medical device networks are larger, more complicated and more mission-critical today than they have ever been. Hospitals in Canada are supporting these networks with ongoing interdepartmental communication, clear departmental responsibilities, and a regular preventive maintenance schedule. In addition, more hospitals are layering digital monitoring solutions on top of their overall network maintenance strategy.

The American Association of Immunologists (AAI) has named Betty Diamond, MD, professor at The Feinstein Institute for Medical Research, to its inaugural class of distinguished fellows

Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies against cancers and infectious diseases to transform the fight against solid tumors and infectious diseases, today announces its business update for the quarter ending March 31, 2019.

Cold Spring Harbor Laboratory (CSHL) has received a USD $5 million donation from BGI Group, the global genomics leader headquartered in Shenzhen, China

Abiomed (NASDAQ:ABMD) announces the U.S. FDA has approved the expansion of the Impella 5.0 and Impella LD PMA labeling for the treatment of cardiogenic shock.